<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01864356</url>
  </required_header>
  <id_info>
    <org_study_id>NT-03</org_study_id>
    <nct_id>NCT01864356</nct_id>
  </id_info>
  <brief_title>A Multi-Center Study To Evaluate Multiple Doses of NT100 Following IVF In Women With Repeated IVF Failures (Thrive-IVF)</brief_title>
  <acronym>Thrive-IVF</acronym>
  <official_title>A Randomized, Double Blind, Multi-Center, Placebo Controlled Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Doses Of NT100 Following IVF In Women With A History Of Repeated IVF Failures (Thrive-IVF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nora Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nora Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and tolerability of multiple
      doses of subcutaneous NT100 vs placebo following in vitro fertilization (IVF) in women with a
      history of repeated IVF failures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NT-03 will be a randomized, double blind, multi-center, placebo controlled study of multiple
      doses of subcutaneous NT100 following IVF in women with a history of repeated IVF failures.
      Approximately 150 subjects will be randomized in a 1:1:1 ratio to receive subcutaneous NT100
      low dose, NT100 high dose, or placebo, qd for up to 4 weeks.

      Screening will include a standard IVF stimulation protocol, followed by fertilization and
      culture of embryos. If the subject remains eligible, she will be randomized to receive study
      drug. All subjects will be followed for 4 weeks after the last dose of study drug. At Week 10
      of gestation, subjects who are pregnant will roll over into a follow-up study (NT-04) to
      assess subsequent pregnancy, delivery, and neonatal outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing clinical pregnancy rate</measure>
    <time_frame>Week 8 of gestation</time_frame>
    <description>The primary efficacy outcome measure is the ongoing clinical pregnancy rate at Week 8 of gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical evidence of pregnancy rate (as measured by hCG)</measure>
    <time_frame>Week 4 of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing clinical pregnancy rate</measure>
    <time_frame>Weeks 6 and 10 of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate following embryo transfer</measure>
    <time_frame>Week 8 of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events and serious adverse events</measure>
    <time_frame>through 4 weeks after last dose of study drug (up to Week 10 of gestation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in clinical laboratory parameters following study drug exposure</measure>
    <time_frame>through 4 weeks after the last dose of study drug (up to Week 10 of gestation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate to severe ovarian hyperstimulation syndrome (OHSS) rate</measure>
    <time_frame>through Week 10 of gestation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Repeated IVF Failure</condition>
  <arm_group>
    <arm_group_label>NT100 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NT100 Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NT100 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NT100 Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NT100</intervention_name>
    <arm_group_label>NT100 Dose 1</arm_group_label>
    <arm_group_label>NT100 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-menopausal female 21-38 years of age at screening

          -  History of repeated IVF failures despite transfer of good-quality embryos, defined as
             follows:

          -  ...1) 3 or more IVF cycles involving transfer of at least two good-quality
             cleavage-stage embryos or at least one good-quality blastocyst (2010 SART (Society for
             Assisted Reproductive Technologies) grading criteria)that resulted in one of the
             following outcomes:

          -  * .....a) no pregnancy

          -  * .....b) biochemical pregnancy

          -  * .....c) spontaneous abortion of an intrauterine clinical pregnancy before or equal
             to completed Week 8 of gestation

          -  ...2) At least two of the eligible IVF failures must have involved transfer of fresh
             embryos

          -  ...3) At least two of the eligible IVF failures must have involved retrieval of at
             least 5 oocytes

          -  ...4) No live birth, abortion later than Week 8 of gestation, or stillbirth may have
             occurred since the first of these IVF failures

          -  Body mass index (BMI) of 19-38 kg per m2 at screening

          -  TSH (thyroid-stimulating hormone) less than or equal to 4.0 mIU/L(milli-International
             units per Liter) for subjects with no history of hypothyroidism, or TSH less than or
             equal to 2.5 mIU/L for subjects with a history of hypothyroidism, at screening

        Exclusion Criteria:

          -  Prior diagnosis of moderate or severe ovarian hyperstimulation syndrome (OHSS)

          -  Clinically confirmed polycystic ovary syndrome (PCOS)

          -  History of a major congenital anomaly in the subject, her current male partner, or
             first degree relative of either the subject or her current male partner

          -  Known karyotype abnormalities in either the subject or her current male partner /
             sperm donor

          -  Any prior pregnancy terminated for a fetal medical condition

          -  History of severe (stage IV) endometriosis

          -  Current or past systemic autoimmune disease

          -  Any uncontrolled clinically significant medical condition (e.g. asthma, Type II
             diabetes, infection)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HRC Fertility</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HRC Fertility</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HRC Fertility</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reproductive Associates of Delaware</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Fertility Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Fertility Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVF and Fertility Center of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Reproductive Specialists</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility Centers of Illinois / River North IVF Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility Centers of Illinois / Highland Park IVF Center</name>
      <address>
        <city>Highland Park</city>
        <state>Illinois</state>
        <zip>60035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shady Grove Fertility</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston IVF</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Reproductive Health</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Main Line Fertility Center</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Assisted Reproduction</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Fertility Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Reproductive Medicine</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Fertility Center</name>
      <address>
        <city>Pleasant Grove</city>
        <state>Utah</state>
        <zip>84062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IVF failure</keyword>
  <keyword>Repeated IVF failure</keyword>
  <keyword>Implantation failure</keyword>
  <keyword>Repeated implantation failure</keyword>
  <keyword>IVF</keyword>
  <keyword>NT100</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

